Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "500k fc points price Buyfc26coins.com is FC 26 coins official site..uOKm"

Looking for quality documents?
external link icon
Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements
WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 0.375% Convertible Senior Notes due 2024 (the “2024 Notes”) and certain new investors, pursuant to which Repligen will issue $600 million aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the “New Notes”). Approximately $309.9 million principal amount of the New Notes will be issued in exchange for approximately $217.7 million principal amount of 2024 Notes (the “Exchange Transactions”) and approximately $290.1 million principal amount of the New Notes will be issued for cash (the “Subscription Transactions”, and together with the Exchange Transactions, the “Transactions”). The conversion price for the New Notes will initially be approximately $203.06 per share of Repligen’s common stock, which represents a conversion
external link icon
Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic Solutions
Proposed A RTeSYN a cquisition adds gold standard single - use downstream bioprocessing s ystems
Advances Repligen’s S ystems strategy in Filtration and Chromatography , c omplement ing TangenX ® F lat S heet cassettes and OPUS ® PP C Completes acquisition of Non-Metallic Solutions (NMS), complementing our recent acquisition of EMT and further strengthens our single-use flow paths, durable plastics and assembly portfolio
WALTHAM, Mass., Oct. 27, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held ARTeSYN Biosolutions (“ARTeSYN”) for approximately $200 million, comprised of approximately $130 million in cash and approximately $70 million in Repligen common stock. ARTeSYN Biosolutions is projected to generate approximately $30 million in revenue (pro forma) in 2020, led by the success of its
video icon
Biologics concentration measurement with the FlowVPX during the UF/DF process in drug substance mftg (Bristol-Myers Squibb)
The FlowVPX System was used as an in-line instrument for product concentration measurement during UF/DF operations, with orthogonal offline testing done to check comparability. The FlowVPX device has generated significant interest for high concentration UF/DF processes in particular (less than 150 g/L) since overconcentration can result in precipitation. The FlowVPX System has significant potential for GMP and commercial biologics manufacturing with the development of single use flow cells by the vendor. Extensive testing was done using small and pilot scale UF/DF operations with several biologic drugs molecules from the company’s portfolio.  The FlowVPX instrument demonstrated acceptable comparability (within 5% difference) with orthogonal A280 based protein concentration measurements for all molecules tested. Accuracy and precision were equivalent for all flow cells and scales tested, suggesting the FlowVPX can be a robust reliable in-line instrument in GMP settings. Speaker: Jay West, Ph.D., Principal Scientist Biologics Process Development – BMS.
external link icon
Repligen Reports Second Quarter 2017 Financial Results
Record quarterly revenue of $32.5 million First half 2017 revenue growth of 16% or 18% at constant currency Enters agreement to acquire Spectrum, Inc., which closed August 1 Prices follow-on offering which netted proceeds of $129 million Raises EPS guidance for 2017 WALTHAM, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter ended June 30, 2017. Detailed in this press release are the Company's performance highlights for the quarter, followed by updated financial guidance for the year 2017 and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said “I’m extremely pleased with our accomplishments and performance during the second quarter.  We executed on our financial and strategic goals, reporting record quarterly revenue and year-to-date revenue growth of 18%. We signed
publications icon
Validating Protein Concentration of Antibody-Drug Conjugates with the CTech™ SoloVPE® System
 UV-Vis spectroscopy is the simplest and most common method to determine protein concentration of ADCs; however, traditional fixed-pathlength spectrophotometers have issues. Authors: Nigel Herbert, Joshua Das, Priya Patel-Abbvie
external link icon
Repligen Announces Acquisition of Chromatography Technology Platform "Plug and Play" Products Create Broad Opportunity in Biopharmaceutical Manufacturing
external link icon
Repligen Reports Third Quarter 2017 Financial Results
Record quarterly revenue of $36.6 million represents 48% year-over-year growth
Year-to-date revenue of $99.6 million represents 26% year-over-year growth Spectrum contributes revenue of $7.6 million in first two months of ownership WALTHAM, Mass., Nov. 09, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter ended September 30, 2017. Detailed in this press release are the Company's performance highlights for the quarter, followed by updated financial guidance for the year 2017 and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said “I’m very pleased with our overall performance in the third quarter. We closed on the Spectrum acquisition in August and our new colleagues delivered terrific results, with greater than 30% year-on-year revenue growth for the first two months of ownership.
external link icon
Repligen Launches OPUS(R) Ready-to-Use Chromatography Columns With Largest Capacity Available on the Market
WALTHAM, Mass., March 26, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN), a technology leader in pre-packed columns for the cost-effective purification of biologic drugs, today announced the commercial launch of its OPUS ® 45 cm diameter columns ("OPUS 45") with the largest capacity currently available on the market. OPUS columns, which now range from 1.2 cm to 45 cm in diameter, are delivered packed with chromatography media used to purify monoclonal antibodies and other biologic drugs. OPUS technology increases facility flexibility, improves the speed of process development and reduces the cost of biopharmaceutical manufacturing by decreasing the set-up, cleaning and validation times associated with traditional purification technologies. OPUS 45 was designed to process large single-use bioreactor harvests and will be formally launched at Biopharmaceutical Development & Production Week being held March 24-27 at the Hilton Bayfront Hotel in San Diego. "Since launching
publications icon
Accelerating analytical testing for GMP plasmid production
The challenges associated with gene therapy bioprocessing are numerous and burdensome, from scalability to Cost of Goods control, and from ensuring quality/consistency to accessing sufficient capacity and expertise. The consensus of opinion in the field is that a largely or fully automated process based upon a single, easy-to-use platform would be optimal, as would the adoption of single-use technology. The majority of challenges that arise with testing of gene therapy materials relate to time and accuracy. The CTech™ SoloVPE® and FlowVPX® slope spectroscopy technology is specifically designed to address these very issues Speaker: Paul Mania
publications icon
Viral Filtration Integrity: Validating the Gold Nanoparticle Test with the CTech™ SoloVPE® System White Paper
In this study, gold nanoparticles in downstream bioprocessing are determined utilizing the CTech™ SoloVPE® System with variable pathlength technology to perform the Slope Spectroscopy® method. This paper demonstrates the suitability and utility of applying the SoloVPE System in place of traditional spectrophotometers for supporting in-process viral filtration integrity tests. With the passing of all predefined acceptance criteria, it is concluded that the SoloVPE instrument is capable of measuring the gold particle solution within specified accuracy, repeatability, specificity, and linearity. Authors: Takeda-Ablatt Mahsut, Piyush Jain, Matt Diamond-Jones, Donald Gillies, and Nigel Herbert
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support